Your browser is no longer supported. Please, upgrade your browser.
Settings
RPTX [NASD]
Repare Therapeutics Inc.
Index- P/E- EPS (ttm)-1.69 Insider Own0.10% Shs Outstand36.92M Perf Week7.63%
Market Cap1.25B Forward P/E- EPS next Y-2.87 Insider Trans-98.26% Shs Float36.46M Perf Month3.79%
Income-62.20M PEG- EPS next Q-0.60 Inst Own85.60% Short Float2.10% Perf Quarter20.47%
Sales0.30M P/S4178.75 EPS this Y-242.90% Inst Trans0.30% Short Ratio5.25 Perf Half Y-9.92%
Book/sh7.25 P/B4.61 EPS next Y-15.70% ROA-17.20% Target Price46.50 Perf Year-
Cash/sh8.30 P/C4.03 EPS next 5Y- ROE-21.30% 52W Range21.45 - 46.44 Perf YTD-2.54%
Dividend- P/FCF- EPS past 5Y- ROI-18.50% 52W High-29.26% Beta-
Dividend %- Quick Ratio26.40 Sales past 5Y- Gross Margin- 52W Low53.15% ATR1.58
Employees104 Current Ratio26.40 Sales Q/Q- Oper. Margin- RSI (14)49.65 Volatility5.27% 5.04%
OptionableYes Debt/Eq0.00 EPS Q/Q-61.20% Profit Margin- Rel Volume0.31 Prev Close33.43
ShortableYes LT Debt/Eq0.00 EarningsMay 13 AMC Payout- Avg Volume145.87K Price32.85
Recom2.10 SMA20-0.83% SMA500.61% SMA2003.36% Volume11,211 Change-1.73%
Mar-01-21Initiated Berenberg Buy $51
Oct-28-20Initiated Northland Capital Outperform $38
Jul-14-20Initiated Piper Sandler Overweight
Jul-14-20Initiated Morgan Stanley Overweight $37
Jul-14-20Initiated Goldman Neutral $27
Jul-14-20Initiated Cowen Outperform
Jun-07-21 06:25AM  
Jun-02-21 07:00AM  
May-11-21 08:06AM  
May-03-21 07:00AM  
Apr-13-21 07:00AM  
Apr-08-21 11:05AM  
Mar-30-21 04:05PM  
Mar-29-21 04:05PM  
Mar-04-21 04:05PM  
Mar-01-21 10:14AM  
Feb-23-21 07:00AM  
Feb-09-21 07:27AM  
Jan-04-21 07:00AM  
Dec-31-20 04:09PM  
Dec-17-20 04:05PM  
Dec-15-20 10:46PM  
Nov-23-20 07:00AM  
Nov-11-20 04:05PM  
Sep-21-20 03:55PM  
Sep-09-20 07:00AM  
Aug-13-20 04:05PM  
Jul-29-20 06:00AM  
Jul-14-20 09:30AM  
Jul-02-20 07:30PM  
Jun-23-20 04:05PM  
Jun-18-20 09:56PM  
Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada. The company use its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing CCNE1-SL inhibitor, a proprietary drug discovery program for tumors with amplification of CCNE1; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montreal, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Foley ToddDirectorJun 09Sale34.6815,523538,2752,330,983Jun 10 04:05 PM
GADICKE ANSBERT10% OwnerJun 09Sale34.6835,2301,221,6334,082,995Jun 10 04:04 PM
Segal Lloyd MitchellPresident and CEOJun 09Sale35.001,57655,16096,008Jun 10 06:35 PM
Foley ToddDirectorJun 08Sale33.2011,544383,2542,346,506Jun 10 04:05 PM
GADICKE ANSBERT10% OwnerJun 08Sale33.2026,200869,8254,118,225Jun 10 04:04 PM
Foley ToddDirectorJun 07Sale32.6810,186332,8502,358,050Jun 07 06:40 PM
GADICKE ANSBERT10% OwnerJun 07Sale32.6823,117755,4014,144,425Jun 07 06:39 PM
Segal Lloyd MitchellPresident and CEOJun 04Option Exercise1.645,0008,18510,000Jun 07 06:36 PM
Foley ToddDirectorJun 04Sale30.985,612173,8422,368,236Jun 07 06:40 PM
GADICKE ANSBERT10% OwnerJun 04Sale30.9812,736394,5224,167,542Jun 07 06:39 PM
Segal Lloyd MitchellPresident and CEOJun 04Sale30.9429,352908,10997,584Jun 07 06:36 PM
Segal Lloyd MitchellPresident and CEOJun 04Sale31.255,000156,2505,000Jun 07 06:36 PM
Foley ToddDirectorJun 03Sale31.929,824313,5822,373,848Jun 07 06:40 PM
GADICKE ANSBERT10% OwnerJun 03Sale31.9222,296711,6884,180,278Jun 07 06:39 PM
Segal Lloyd MitchellPresident and CEOJun 03Sale31.746,648211,008126,936Jun 07 06:36 PM
Foley ToddDirectorJun 02Sale31.862,73887,2272,383,672Jun 02 05:40 PM
GADICKE ANSBERT10% OwnerJun 02Sale31.866,215197,9994,202,574Jun 02 05:39 PM
Foley ToddDirectorJun 01Sale32.506,671216,8082,386,410Jun 02 05:40 PM
GADICKE ANSBERT10% OwnerJun 01Sale32.5015,141492,0824,208,789Jun 02 05:39 PM
Foley ToddDirectorMay 28Sale32.677,377241,0072,393,081Jun 02 05:40 PM
GADICKE ANSBERT10% OwnerMay 28Sale32.6716,742546,9614,223,930Jun 02 05:39 PM
Foley ToddDirectorMay 27Sale32.973,503115,4922,400,458May 27 07:55 PM
GADICKE ANSBERT10% OwnerMay 27Sale32.977,951262,1414,240,672May 27 07:41 PM
Foley ToddDirectorMay 26Sale32.7610,590346,9192,403,961May 27 07:55 PM
GADICKE ANSBERT10% OwnerMay 26Sale32.7624,036787,3994,248,623May 27 07:41 PM
Foley ToddDirectorMay 25Sale32.882,89695,2232,414,551May 27 07:55 PM
GADICKE ANSBERT10% OwnerMay 25Sale32.886,572216,0944,272,659May 27 07:41 PM
Foley ToddDirectorMay 24Sale34.129,782333,7952,417,447May 24 08:13 PM
GADICKE ANSBERT10% OwnerMay 24Sale34.1222,200757,5404,279,231May 24 08:12 PM
Foley ToddDirectorMay 21Sale34.80133,3594,640,8932,427,229May 24 08:13 PM
GADICKE ANSBERT10% OwnerMay 21Sale34.80302,66910,532,8814,301,431May 24 08:12 PM
Segal Lloyd MitchellPresident and CEOMay 20Sale35.033,770132,065133,584May 21 04:02 PM
GADICKE ANSBERT10% OwnerMay 20Sale34.699,957345,4284,604,100May 20 07:56 PM
Foley ToddDirectorMay 20Sale34.694,387152,1942,560,588May 20 07:21 PM
GADICKE ANSBERT10% OwnerMay 19Sale34.4813,543466,9654,614,057May 20 07:56 PM
Foley ToddDirectorMay 19Sale34.485,968205,7782,564,975May 20 07:21 PM
Segal Lloyd MitchellPresident and CEOMay 19Sale35.063,800133,228137,354May 20 06:19 PM
GADICKE ANSBERT10% OwnerMay 18Sale34.1623,404799,5714,649,434May 20 07:56 PM
Foley ToddDirectorMay 18Sale34.1610,312352,2982,592,777May 20 07:21 PM
Segal Lloyd MitchellPresident and CEOMay 18Sale35.001,80063,000141,154May 20 06:19 PM
Zinda MichaelEVP, Chief Science OfficerMay 17Sale32.7115,000490,71035,533May 18 05:53 PM
Segal Lloyd MitchellPresident and CEOApr 15Sale35.015,512192,975142,954Apr 19 05:44 PM
Foley ToddDirectorMar 12Sale28.18376,41210,607,2902,627,360Mar 15 05:11 PM
GADICKE ANSBERT10% OwnerMar 12Sale28.18695,00019,585,1004,697,109Mar 15 05:10 PM
Zinda MichaelEVP, Chief Science OfficerDec 29Sale33.6719,696663,09750,533Dec 30 05:10 PM
Zinda MichaelEVP, Chief Science OfficerDec 28Option Exercise2.06489985,277Dec 30 05:10 PM
Zinda MichaelEVP, Chief Science OfficerDec 28Sale34.2515,048515,35970,229Dec 30 05:10 PM
Zinda MichaelEVP, Chief Science OfficerDec 24Option Exercise2.0643289185,661Dec 28 04:40 PM
Zinda MichaelEVP, Chief Science OfficerDec 24Sale33.1443214,31685,229Dec 28 04:40 PM
Zinda MichaelEVP, Chief Science OfficerDec 23Option Exercise2.2216,23536,081101,464Dec 28 04:40 PM
Zinda MichaelEVP, Chief Science OfficerDec 23Sale33.6616,235546,41785,229Dec 28 04:40 PM
Zinda MichaelEVP, Chief Science OfficerDec 22Option Exercise1.9041,31278,510126,541Dec 28 04:40 PM
Zinda MichaelEVP, Chief Science OfficerDec 22Sale33.3841,3121,379,20085,229Dec 28 04:40 PM
Zinda MichaelEVP, Chief Science OfficerDec 21Option Exercise2.4240,00097,000125,229Dec 22 04:37 PM
Zinda MichaelEVP, Chief Science OfficerDec 21Sale33.0840,0001,323,20085,229Dec 22 04:37 PM
Zinda MichaelEVP, Chief Science OfficerDec 18Option Exercise2.068,32117,15893,550Dec 18 08:29 PM
Zinda MichaelEVP, Chief Science OfficerDec 18Sale34.608,321287,92585,229Dec 18 08:29 PM
Zinda MichaelEVP, Chief Science OfficerDec 16Option Exercise1.648,95614,66194,185Dec 18 08:29 PM
Zinda MichaelEVP, Chief Science OfficerDec 16Sale35.268,956315,76785,229Dec 18 08:29 PM